Introduction {#Sec1}
============

Usher syndrome (USH) is a rare autosomal recessive disease that associates retinitis pigmentosa (RP), sensorineural hearing loss (SNHL) and, in some cases, vestibular dysfunction. It is the most common form of hereditary disease combining hearing and vision impairment, with a prevalence ranging from 3 to 6.2 per 100,000^[@CR1],[@CR2]^. Three types of USH are distinguished depending on the severity and progression of the pathology: Type 1 (USH I) is typically characterized by a severe-profound congenital hearing loss, onset of RP usually within the first decade of life, and vestibular dysfunction. Type 2 (USH II) patients present with a moderate-severe congenital hearing impairment, a pubertal onset of RP and normal vestibular function. Type 3 (USH III) is defined by progressive hearing loss starting after post-lingual phase and an age-variable onset of RP, whereas the vestibular dysfunction is variable^[@CR3]^. Despite the three major divisions of the disorder, some patients display a clinical profile not matching any of these categories, being classified as atypical USH.

As well as clinically, USH is genetically heterogeneous. To date, 13 genes have been associated with the disease and these do not explain all the reported cases, suggesting other still unknown genes may be responsible for the disorder^[@CR4]^.

USH I is commonly caused by mutations in six genes: *MYO7A*, *USH1C*, *CDH23*, *PCDH15*, *USH1G* and *CIB2*. On the other hand, *USH2A*, *ADGRV1* and *WHRN* are the three genes usually responsible for USH II, whilst the *CLRN1* gene is the only one currently associated to USH III cases.

In addition, other genes have been related to the disease. The *PDZD7* gene has been reported to behave as a modifier of retinal disease with *USH2A* and a contributor to digenic inheritance with *ADGRV1*^[@CR5]^. Recently, *HARS* was proposed as a novel causative gene of USH III, based on a mutation found in two patients^[@CR6]^ and *CEP250* has been reported as responsible for an atypical Usher syndrome with SNHL and a relatively mild RP^[@CR7]^.

Most of the USH-causing mutations are private and most of the involved genes are of a large size. These issues can be overcome with the use of high-throughput sequencing (HTS) tools, which enable a rapid, feasible method for the genetic diagnosis of the disease, and they are being increasingly employed^[@CR8]--[@CR12]^. The main objective of the present study is the molecular diagnosis of a large cohort of USH patients by means of a HTS screening. Thus, we developed a custom targeted exome design, including the ten disease causative genes and four additional candidates, for its use in Ion Torrent platforms.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

A cohort of 77 USH patients was selected for this study. The probands were classified into the different USH subtypes according to their clinical records. The data (when feasible) consisted of the patient's ophthalmological studies, including best-corrected visual acuity measurements (BCVA), fundus ophthalmoscopy, visual field examination and electrophysiological examination; and audiological tests^[@CR13]--[@CR15]^. Hearing loss severity was established as mild (between \>25 and ≤40 dB), moderate (between \>40 and ≤70 dB) or severe/profound (\>70 dB). Patients presenting a bilateral severe congenital hearing loss (\>70 dB), early RP onset and altered vestibular function were diagnosed as USH I. Patients suffering from bilateral congenital moderate-severe hearing loss (40--70 dB) and adolescent-to-adult onset of RP were categorized as USH II. If the patients displayed progressive hearing loss, with or without vestibular dysfunction, and late onset RP, were recognized as USH III. Patients with a profile not quite matching any of these three categories were diagnosed as atypical USH cases. When the clinical data was insufficient, the type was stated as general USH. For case RP1973, further ophthalmological examinations were performed, which included measurements of fundus autofluorescence (FAF), optical coherence tomography (OCT) (acquired with a Heidelberg Spectralis OCT Bluepeak) and visual fields 30-2 and 120-2 strategies by the Humphrey Visual Field Analyzer. Full-field electroretinography was performed according to the International Society for Clinical Electrophysiology of Vision Standards^[@CR16]^.

From all the patients included, 19 were assigned to a test group in order to evaluate the sequencing platform performance. Eight cases out of these already had a complete molecular diagnosis (at least two USH causative mutations) and 11 where partially solved with only one previously known disease causing mutation. The test group comprised a total of 4 Copy Number Variations (CNVs) and 22 point mutations, represented by variants of different nature (Table [1](#Tab1){ref-type="table"}). Finally, a cohort of 58 previously unscreened USH patients of Spanish origin were recruited for this study in order to determine their genetic diagnosis. Among these to be characterized, 15 were USH I, 31 USH II, and 12 undetermined USH.Table 1Details of the test group formed by patients carrying previously detected variants in USH genes.PatientPhaseGeneVariant typeNucleotideProteinClassReferenceDetectionRP692M*HetUSH2A*Missensec.14453C \> Tp.Pro4818LeuUV3Aller *et al*.^[@CR54]^Yes*HetUSH2A*Nonsensec.10102C \> Tp.Gln3368\*UV4Jaijo *et al*.^[@CR55]^Yes*HetUSH2A*Frameshiftc.5278delGp.Asp1760Metfs\*10UV4Jaijo *et al*.^[@CR55]^YesRP1034*HetCDH23*Missensec.8311G \> Ap.Gly2771SerUV3Oshima *et al*.^[@CR56]^Yes*HetPCDH15*Nonsensec.733C \> Tp.Arg245\*UV4Ben-Yosef *et al*.^[@CR57]^Yes*HetPCDH15*CNVDeletion exon 3---UV4Aller *et al*.^[@CR30]^NoRP1286*HetPCDH15*Frameshiftc.1304_1305insCp.Thr436Tyrfs\*12UV4Jaijo *et al*.^[@CR58]^AFRRP1495*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21UV4Liu *et al*.^[@CR59]^YesRP1522*HetUSH2A*CNVDeletion exon 20---UV4Aparisi *et al*.^[@CR8]^No*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21UV4Liu *et al*.^[@CR59]^YesRP1537*HetUSH2A*Missensec.2276G \> Tp.Cys759PheUV4Dreyer *et al*.^[@CR60]^YesRP1608*HomUSH2A*Missensec.9799T \> Cp.Cys3267ArgUV4Aller *et al*.^[@CR54]^YesRP1638*HetUSH2A*CNVDeletion exons 5_9---UV4Garcia-Garcia *et al*.^[@CR36]^No*HetUSH2A*Nonsensec.5549dupA^a^p.Tyr1850\*UV4Garcia-Garcia *et al*.^[@CR61]^YesRP1639*HomUSH2A*Missensec.10712C \> Tp.Thr3571MetUV3Aller *et al*.^[@CR54]^YesRP1740*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21UV4Liu *et al*.^[@CR59]^YesRP1746*HetUSH2A*Missensec.9799T \> Cp.Cys3267ArgUV4Aller *et al*.^[@CR54]^YesRP1757*HetMYO7A*In-frame deletionc.655_660delp.Ile219_His220delUV3Jaijo *et al*.^[@CR62]^YesRP1768*HetMYO7A*Frameshiftc.1623dupCp.Lys542Glnfs\*5UV4Bharadwaj *et al*.^[@CR63]^AFRRP1780*HetPCDH15*Splice-sitec.3717 + 2dupT---UV4Jaijo *et al*.^[@CR58]^Yes*HetPCDH15*Nonsensec.7C \> Tp.Arg3\*UV4Ahmed *et al*.^[@CR64]^YesRP1888*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21UV4Liu *et al*.^[@CR59]^YesRP1895*HomADGRV1*CNVDuplication exons 79_83---UV4Besnard *et al*.^[@CR38]^NoRP1906*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21UV4Liu *et al*.^[@CR59]^YesRP2019*HetCDH23*Missensec.4488G \> Cp.Gln1496HisUV4Bolz *et al*.^[@CR65]^YesRP2024*HetCDH23*Missensec.7823G \> Ap.Arg2608HisUV3Astuto *et al*.^[@CR66]^YesAbbreviations: Het, Heterozygosis; Hom, Homozygosis; AFR, After Filters Relaxation.^a^This variant was wrongly named in the previous study of reference (Garcia-Garcia *et al*., 2011) as c.5540dupA.These variants had been previously discovered through other HTS platforms or other variant detection techniques such as MLPA, Sanger sequencing or SNP array.

Segregation analysis was performed by conventional Sanger sequencing when DNA samples of family members were available.

Ethics Statement {#Sec4}
----------------

This study was approved by the Hospital La Fe Ethics Committee and authorizations from all the patients and the participating relatives were obtained by signing an informed consent form. All research was performed in accordance with the relevant guidelines and regulations.

Samples {#Sec5}
-------

Genomic DNA (gDNA) from the probands was obtained and purified using standard procedures. The concentration of the resulting DNA samples was determined with Nanodrop and Qubit fluorometer (Thermo Fisher Scientific).

Targeted USH exome sequencing design {#Sec6}
------------------------------------

A customized AmpliSeq panel was designed using Ion AmpliSeq Designer tool from Thermo Fisher Scientific ([www.ampliseq.com](http://www.ampliseq.com)) to generate the targeted library. The designed targeted exome (Table [2](#Tab2){ref-type="table"}) included all exons contemplated in all isoforms of 14 genes: the 10 USH causative genes (*MYO7A*, *USH1C*, *CDH23*, *PCDH15*, *USH1G*, *CIB2*, *USH2A*, *ADGRV1*, *WHRN* and *CLRN1*), the additional locus comprising the c.7595 − 2144A \> G intronic mutation in *USH2A*^[@CR17]^, and 4 USH associated genes (*HARS*, *PDZD7*, *CEP250* and *C2orf71*).Table 2Details of the target region studied in this study.ChrGene/*locus*IsoformCoding exonsAdditional exonsSize (bp)Number of ampliconsDesign coverage11*MYO7A*NM_000260.348376428898.6%11*USH1C*NM_15367627233343894.2%10*CDH23*NM_022124.56941184912099.5%10*PCDH15*NM_033056.3321182846798.2%17*USH1G*NM_173477.231144612100%15*CIB2*NM_006383.261684895%1*USH2A*NM_2069337111704313498.9%1216064460--216064620^a^---------1601100%5*ADGRV1*NM_032119.38912072118199.4%9*WHRN*NM_015404122296426100%3*CLRN1*NM_1748783610519100%5*HARS*NM_002109132179014100%10*PDZD7*NM_001195263.117---34743197.5%20*CEP250*NM_007186.432---796958100%2*C2orf71*NM_001029883.22---39072399.6%Chr, Chromosome number.^a^Region of the *USH2A* PE (Pseudo-exon 40) where mutation c.7595 − 2144A \> G is located.The design included a padding of 10 bp of the flanking intronic regions. All the target regions were covered by 810 amplicons, computing a total panel size of 147.95 kb.

Sequence enrichment and HTS {#Sec7}
---------------------------

The amplification of the targets was performed according to the Ion AmpliSeq Library Kit 2.0 protocol (Thermo Fisher Scientific) for Ion Torrent sequencing. The sequencing was carried out with a theoretical minimum coverage of 500x either on the PGM (Ion 318 chip, 500 flows) or Proton system (Ion PI chip, 520 flows).

Variant filtering and analysis {#Sec8}
------------------------------

The resulting sequencing data were analyzed with Ion Reporter Software tool (<https://ionreporter.thermofisher.com>) in regard to the human assembly GRCh37/hg19. The annotated variants were filtered according to a Minor Allele Frequency (MAF) value ≤0.01, the frequency of the variants was explored in the Exome Aggregation Consortium (ExAC) database, their annotation in the dbSNP ([www.ncbi.nlm.nih.gov/SNP/](http://www.ncbi.nlm.nih.gov/SNP/)), their description in the Usher syndrome mutation database (<https://grenada.lumc.nl/LOVD2/Usher_montpellier/>) and the mutation type.

In order to determine the pathogenicity of novel missense or splice-site mutations, the variants were analyzed using several *in silico* prediction tools according to the nature of the mutation. Aminoacid change effects were examinated using the *SIFT*^[@CR18]^, *PolyPhen-2*^[@CR19]^ and *PROVEAN*^[@CR20]^ programs and the additional tools *ATGpr*^[@CR21]^, *NetStart*^[@CR22]^ and *TIS Miner*^[@CR23]^ were applied when concerning translation start loss variants. Putative variants affecting the splicing pattern were investigated with the *Human Splicing Finder 3*.*1*^[@CR24]^, *MaxEnt*^[@CR25]^ and *NNSplice*^[@CR26]^ algorithms.

All the putative pathogenic variants were validated through conventional Sanger sequencing. All the poorly or null covered regions were screened by conventional Sanger for all the cases with only one or none putative disease causing mutations detected through HTS. Additionally, the same patients were screened by Sanger sequencing for recently identified deep intronic mutations that were published after the start of this study and could therefore not be included in the panel design: four in *USH2A*, namely c.14134 − 3169A \> G^[@CR27]^, c.5573 − 843A \> G, c.8845 + 628C \> T, c.9959 − 4159A \> G^[@CR28]^; and variant c.254--649T \> G of *CLRN1*^[@CR29]^.

Copy Number Variation analysis {#Sec9}
------------------------------

The screening for large rearrangements was performed in all patients where either none or only one mutation was detected with the panel, using either multiplex ligation-dependent probe amplification (MLPA) or a custom microarray-based Comparative Genomic Hybridisation (aCGH).

The MLPA technique (MRC-Holland) allows the identification of large rearrangements for the *USH2A* (probemixes P361 and P362) and *PCDH15* (probemix P292) genes.

In order to screen possible CNVs in the remaining genes, aCGH was designed covering all the genes included in this study. The resulting custom 60 K microarray (Agilent Technologies, AMADID-082310) contained 62976 probes. Three DNA samples with known CNVs from the test group (RP1895, RP1522, RP1034) were used as positive controls in the first batch of the analysis, in order to validate the custom design of the array.The gDNAs were prepared according to the manufacturer's protocol, as described before^[@CR30]^.

Splicing Effect Analysis by Minigenes {#Sec10}
-------------------------------------

Minigene assay was performed for all novel intronic mutations found in this study in order to confirm the splicing alterations, adopting a procedure previously described^[@CR31]^ and using HEK293 cells. All experiments were performed in duplicate.

Extended exome screening {#Sec11}
------------------------

Whole exome sequencing (WES) using SureSelect Human All Exon V6 kit (Agilent Techologies) for Illumina platform was performed for sample RP1973 to discard mutations in other genes, in view of the results obtained for this case.

Results {#Sec12}
=======

Test group {#Sec13}
----------

The sequencing results allowed us to identify 20 of the 22 point mutations from the positive controls, while none of the CNVs was detected. When forcing a general parameters relaxation, the two previously undetected changes consisting of frameshift duplications were then recognized. These results and detailed information are summarized in Table [1](#Tab1){ref-type="table"}.

In this study, the second disease causing mutation was detected in 7 out of the 11 patients included in the test group in whom only one of the pathological alleles was previously registered and, therefore, their genetic diagnosis was fulfilled (Table [3](#Tab3){ref-type="table"}). These included 6 novel mutations: two nonsense mutations, two CNVs, 1 frameshift and 1 splice-site mutation.Table 3Causative mutations and putative pathogenic variants identified in this studyPatientType*PhaseGene*Variant typeNucleotideProteinReference or Class**Patients with two pathogenic mutations**RP580MUSH II***Het**ADGRV1*Frameshiftc.5944dupTp.Ser1982Phefs\*2Novel UV4***HetADGRV1*CNVDup. exons 79--83---Besnard *et al*.^[@CR38]^RP689USH I*HomMYO7A*Missensec.1190C \> Ap.Ala397AspAdato *et al*.^[@CR67]^RP905USH II*HomUSH2A*Frameshiftc.12093delCp.Tyr4031\*Garcia-Garcia *et al*.^[@CR61]^RP956USH II*HomADGRV1*Missensec.17933A \> G^s^p.His5978ArgBesnard *et al*.^[@CR38]^RP957USH I*HomCDH23*Missensec. 6049G \> Ap.Gly2017SerRoux *et al*.^[@CR68]^RP971USH II*HetUSH2A*Nonsensec.12729G \> Ap.Trp4243\*Neveling *et al*.^[@CR69]^*HetUSH2A*Missensec.1531G \> Ap.Glu511LysBaux *et al*.^[@CR70]^RP1350USH II***Het**ADGRV1*Nonsensec.16886G \> Ap.Trp5629\*Novel UV4*Het**ADGRV1*Missensec.4102A \> Tp.Asn1368TyrNovel UV4**RP1353USH II***Hom**ADGRV1*Splice-sitec.5314 − 5T \> Ap.Asn1772\*Novel UV4**RP1399USH II***Hom**USH2A*Nonsensec.11404G \> Tp.Glu3802\*Novel UV4**RP1420USH I*HomCDH23*Nonsensec.7221C \> Ap.Tyr2407\*Besnard *et al*.^[@CR50]^RP1495^t^USH II*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^***Het**USH2A*CNVDel. exons 22--49---Novel UV4**RP1506BUSH II***Het**USH2A*Nonsensec.10008C \> Ap.Cys3336\*Novel UV4*Het**USH2A*Nonsensec.5416A \> Tp.Lys1806\*Novel UV4**RP1564USH II***Hom**ADGRV1*Missensec.14159C \> T** ^**s**^**p.Pro4720LeuNovel UV4**RP1565USH II***Hom**USH2A*Nonsensec.11404G \> Tp.Glu3802\*Novel UV4**RP1567USH II*HetMYO7A*Missensec.5516T \> Cp.Leu1839ProAparisi *et al*.^[@CR8]^***Het**MYO7A*Start lossc.3G \> Ap.Met1?Novel UV4**RP1580USH I*HomMYO7A*Nonsensec.6070C \> Tp.Arg2024\*Jacobson *et al*.^[@CR71]^RP1686USH II***Hom**ADGRV1*Nonsensec.18054G \> Ap.Trp6018\*Novel UV4**RP1694USH I***Hom**USH1G*Missensec.1196T \> Cp.Leu399ProNovel UV3**RP1746^t^USH II*HetUSH2A*Missensec.9799T \> Cp.Cys3267ArgAller *et al*.^[@CR54]^*HetUSH2A***Splice-sitec.12295 − 1G \> Ap.Thr4099Vfs\*2Novel UV4**RP1748USH I*HomUSH2A***Nonsensec.2950C \> Tp.Gln984\*Novel UV4**RP1757^t^Atypical*HetMYO7A*IF deletionc.655_660del^s^p.Ile219_His220delJaijo *et al*.^[@CR62]^***Het**MYO7A***Missensec.4489G \> C^s^p.Gly1497ArgBonnet *et al*.^[@CR51]^RP1768^t^USH I*HetMYO7A*Frameshiftc.1623dupCp.Lys542Glnfs\*5Bharadwaj *et al*.^[@CR63]^*HetMYO7A***Nonsensec.6232A \> Tp.Lys2078\*Novel UV4**RP1806USH I*HomUSH1G*Nonsensec.805C \> T^s^p.Arg269\*Aparisi *et al*.^[@CR8]^RP1809USH II*HetUSH2A*Pseudo-exonc.7595 − 2144A \> G^s^p.Lys2532Thrfs\*56Vaché *et al*.^[@CR17]^*HetUSH2A*Missensec.12695C \> T^s^p.Pro4232LeuBonnet *et al*.^[@CR51]^RP1811USH II***Hom**USH2A*Nonsensec.7932G \> Ap.Trp2644\*Novel UV4**RP1857USH I***Het**CDH23*Missensec.3115G \> Ap.Val1039MetNovel UV3*Het**CDH23*Missensec.3007T \> Cp.Ser1003ProNovel UV4**RP1869USH II***Hom**USH2A*Missensec.4385C \> Tp.Thr1462IleNovel UV4**RP1872USH II***Hom**USH2A*Splice-sitec.5776 + 1G \> A** ^**s**^**p.Gly1858_Thr1925delNovel UV4**RP1888^t^USH II*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^*HetUSH2A***CNVDup. exons 28--30---Novel UV4**RP1900USH*HetMYO7A***Frameshiftc.1934_1935insCCATp.Met645Ilefs\*67Novel UV4***HetMYO7A***Splice-sitec.1691 − 1G \> Ap.Phe565Argfs\*11Novel UV4**RP1906^t^USH II*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^***Het**USH2A*Nonsensec.9119G \> Ap.Trp3040\*Novel UV4**RP1944USH I*HomMYO7A*Missensec.3503G \> Ap.Arg1168GlnAparisi *et al*.^[@CR8]^RP1967USH I*HetMYO7A*Nonsensec.5392C \> T^s^p.Gln1798\*Bharadwaj *et al*.^[@CR63]^*HetMYO7A*Missensec.5516T \> C^s^p.Leu1839ProAparisi *et al*.^[@CR8]^RP1969USH I***Hom**MYO7A*Frameshiftc.5561dupTp.Gln1855Alafs\*56Novel UV4**RP1973USH II***Het**CEP250*Nonsensec.4006C \> T** ^**s**^**p.Arg1336\*Novel UV4*Het**CEP250*Nonsensec.3337A \> T** ^**s**^**p.Lys1113\*Novel UV4**RP1979USH II*HetUSH2A*Missensec.10712C \> Tp.Thr3571MetAller *et al*.^[@CR54]^*HetUSH2A*Nonsensec.9424G \> Tp.Gly3142\*Baux *et al*.^[@CR72]^RP2005USH II***Het**USH2A*Frameshiftc.4961delGp.Ser1654Ilefs\*11Novel UV4***HetUSH2A*Nonsensec.13822C \> Tp.Arg4608\*Dreyer *et al*.^[@CR73]^RP2007USH I*HomPCDH15*Nonsensec.1737C \> G^s^p.Tyr579\*Jaijo *et al*.^[@CR58]^RP2010USH II*HomUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^RP2011USH II*HetCDH23*Splice-sitec.6050 − 9G \> A---von Brederlow *et al*.^[@CR74]^***Hom**ADGRV1*CNVDel. exons 28--33---Novel UV4**RP2019^t^USH***Het**CDH23*Frameshiftc.8462dupTp.Asp2822Argfs\*5Novel UV4***HetCDH23*Missensec.4488G \> Cp.Gln1496HisBolz *et al*.^[@CR65]^RP2022USH II*HetUSH2A*Frameshiftc.2135delCp.Ser712\*Bernal *et al*.^[@CR75]^***Het**USH2A*Nonsensec.6967C \> Tp.Arg2323\*Novel UV4**RP2023USH II***Het**USH2A*Nonsensec.6157C \> Tp.Gln2053\*Novel UV4***HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^RP2028USH*HetUSH2A*Nonsensec.11864G \> Ap. Trp3955\*Van Wijk *et al*.^[@CR76]^***Het**USH2A*Frameshiftc.13778_13779insTTp.Val4596\*Novel UV4**RP2032USH*HetUSH2A*Missensec.2276G \> Tp.Cys759PheDreyer *et al*.^[@CR60]^*HetUSH2A*Missensec.9799T \> Cp.Cys3267ArgAller *et al*.^[@CR54]^RP2035USH*HomUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^RP2037USH*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^*HetUSH2A*Splice-sitec.949C \> A---Pennings *et al*.^[@CR77]^RP2050USH II*HetUSH2A*Pseudo-exonc.7595 − 2144A \> Gp.Lys2532Thrfs\*56Vaché *et al*.^[@CR17]^*HetUSH2A*Missensec.8254G \> Ap.Gly2752ArgNakanishi *et al*.^[@CR78]^RP2058USH*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^*HetUSH2A*Missensec.802G \> Ap.Gly268ArgBaux *et al*.^[@CR70]^RP2069USH***Het**MYO7A*IF deletionc.5887_5889delTTTp.Phe1963delNovel UV4***HetMYO7A*Missensec.5648G \> Ap.Arg1883GlnOuyang *et al*.^[@CR79]^RP2068USH***Het**USH2A*Frameshiftc.13102dupAp.Ser4368Lysfs\*21Novel UV4*Het**USH2A*Frameshiftc.13926dupAp.Gln4643Thrfs\*40Novel UV4**RP1936USH***Het**ADGRV1*Frameshiftc.1892delCp.Pro631Leufs\*62Novel UV4*Het**ADGRV1*CNVDel. Exon 85---Novel UV4Patients with only one pathogenic mutation**RP681USH***Het**CDH23*Frameshiftc.7279delAp.Thr2427Leufs\*47Novel UV4**RP1222USH II***Het**USH1C*Missensec.1234G \> Ap.Asp412AsnNovel UV3**RP1488USH II*HetADGRV1*Missensec.3151G \> Tp.Asp1051TyrNeveling *et al*.^[@CR69]^RP1571USH***Het**CIB2*Missensec.311G \> Ap.Arg104GlnNovel UV3**RP2020USH I*HetMYO7A*Missensec.3508G \> Ap.Glu1170LysCuevas *et al*.^[@CR80]^RP2034USH*HetUSH2A*Frameshiftc.2299delGp.Glu767Serfs\*21Liu *et al*.^[@CR59]^Het, Heterozygosis; Hom, Homozygosis; PE, Pseudoexon 40; IF, In-Frame; Dup., Duplication; Del., Deletion.^s^Cases where segregation analysis was performed; ^t^Patients previously included in the test group.Novel variants displayed in bold.The novel variants found were categorized based on the guidelines of the clinical and molecular genetics society ([www.emqn.org/emqn/Best+Practice](http://www.emqn.org/emqn/Best+Practice)) and the Unknown Variants classification system (<https://grenada.lumc.nl/LOVD2/Usher_montpellier/>) as pathogenic, probably pathogenic (UV4), possibly pathogenic (UV3), possibly non-pathogenic (UV2) and neutral (UV1) according to bioinformatic predictions and segregation analysis.

Cohort of previously unscreened USH patients {#Sec14}
--------------------------------------------

We identified both pathogenic variants in 45 out of the 58 the analyzed cases and in 6 patients only one mutation was detected. No likely pathogenic mutations were found in other 7 probands.

This work allowed to detect mutations of different nature, from which 42 were novel variants (Table [3](#Tab3){ref-type="table"}). Among these novel changes, we were able to detect 8 missense, 14 nonsense, 11 frameshift, 4 splice-site, 1 start loss variant and 4 large rearrangements (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Regarding all the detected mutations, *USH2A* shows the highest prevalence, accounting for 48% of the causative variants (Fig. [1](#Fig1){ref-type="fig"}).Table 4Summary of the bioinformatics predictions for the novel causative putative mutations detected in this study.Patient*Gene*NucleotideClassProtein function prediction toolsTIS prediction toolsSplicing impact prediction toolsSIFTPPHPROVEANATGprNetStartTIS MinerHSFMaxEntNNSpliceRP1350*ADGRV1*c.4102A \> TUV4DDD---------NNNRP1353*ADGRV1*c.5314 − 5T \> AUV4------------------NWT AS brokenMain AS not recognizedRP1540*MYO7A*c.1816C \> TUV4DDD---------NNNRP1564*ADGRV1*c.14159C \> TUV4DDD---------NNNRP1567MYO7Ac.3G \> AUV4DNNTIS lostTIS lostTIS lostNNNRP1694*USH1G*c.1196T \> CUV3DDN---------NNNRP1746*USH2A*c.12295 − 1G \> AUV4------------------WT AS brokenWT AS brokenMain AS not recognizedRP1857*CDH23*c.3115G \> AUV3DDNNew TISNew TISNew TISNNMain DS not recognizedRP1857*CDH23*c.3007T \> CUV4DDD---------NNNRP1869*USH2A*c.4385C \> TUV4DDD---------NNNRP1872*USH2A*c.5776 + 1G \> AUV4------------------WT DS brokenWT DS brokenMain DS not recognizedRP1900*MYO7A*c.1691 − 1G \> AUV4------------------WT AS broken and NS createdWT AS brokenMain AS not recognizedRP1571*CIB2*c.311G \> AUV3NDD---------NNNRP1222*USH1C*c.1234G \> AUV3DPN---------NNNPPH, PolyPhen-2; TIS, Translation Initiation Site; D, Damaging/Probably damaging/Deleterious (SIFT/PPH/PROVEAN); P, Possibly damaging (PPH); N, Tolerated/Benign/Neutral (SIFT/PPH/PROVEAN); WT, Wild type; AS, Acceptor Site; DS, Donor Site; HSF, Human Splicing Finder.Those variants with concurring results referred as damaging by all of the effect prediction tools of a same category were classified as UV4. The mutations were stated as UV3 when pathogenicity was assessed by two out of the three predictors. Those with neutral or UV2 prognosticated effect were not taken into account as positive results and therefore data for those cases is not shown.Figure 1Recurrence of mutated genes included in the design of this study and distribution of the type of mutations. The data includes all the disease causative variants from the previously unscreened cohort and from the seven ultimately solved patients of the test group, which at the beginning of the study had only one causing mutation identified and the second was finally detected with the technology used in this work. Abbreviations: PE, Pseudo-exon; InDel, Insertion/Deletion; CNV, Copy Number Variation.

Custom aCGH unveiled three CNVs in the *ADGRV1* gene: one large heterozygous duplication involving exons 79--83 in patient RP580, the heterozygous deletion of exon 85 in patient RP1936, and one large homozygous deletion comprising exons 28--33 in proband RP2011. The latter was also suspected beforehand by the null coverage of that region on the HTS sequencing results.

Minigene splice assay analysis {#Sec15}
------------------------------

We detected 3 canonical splice-site mutations (c.1691 − 1G \> A, *MYO7A*; c.5776 + 1G \> A, *USH2A*; c.12295 − 1G \> A, *USH2A*) and one variant with dubious consequences (c.5314 − 5T \> A, *ADGRV1*) (Table [4](#Tab4){ref-type="table"}). These variant candidates were tested through minigenes and for all of them the exon skipping was proved, confirming therefore the pathogenicity of the mutations (Fig. [2](#Fig2){ref-type="fig"}).Figure 2Minigene assay results for the four splicing mutations. The gel electrophoresis displays the splicing outcome of the minigene transcription for the WT and mutant alleles. *In vitro* experiments were performed in duplicate and therefore the results show both repetitions. Sanger sequencing of the results confirm the splicing processes by evidencing the transcript joints. SD6 and SA2 are the exons included in the pSPL3 exon trapping vector used in the assay. (**a**) c.5314 − 5T \> A (*ADGRV1*). Band A corresponds to the correct transcript of exon 25. Band B from the mutant construction denotes the skipping of the same exon. If the transcript harboring the mutation were translated, the newly generated protein would of 1,772 aminoacids in length, p.Asn1772\*. (**b**) c.5776 + 1G \> A (*USH2A*). Band A is the correct transcript corresponding to the exon 28 and Band B is the skipping of the same exon. If the aberrant transcript were translated, it would generate a new truncated protein of 5,134 aminoacids in length, p.Gly1858_Thr1925del. (**c**) c.1691 − 1G \> A (*MYO7A*). Band A corresponds to the correct transcript of exon 25. Band B is the aberrant splicing process due to the new site generated by the lack of a guanine at the acceptor site, entailing therefore a frameshift effect. The fragment C corresponds to de exon skipping of exon 15. If the transcript with the mutation were translated, it would generate the two proteins p. Gly564Alafs\*58 and p.Phe565Argfs\*11. (**d**) c.12295 − 1G \> A (*USH2A*). Band A corresponds to the correct transcript of exon 63 and band B, from the mutant allele, evidences the skipping of the exon. The displayed images of the gels have been cropped to improve the clarity of the presentation, and the full-length gels are presented in Supplementary Fig. [S2](#MOESM1){ref-type="media"}.

For the c.1691 − 1G \> A *MYO7A* mutation, the minigene assay was of particular interest. Besides the skipping of exon 15, the mutant allele displayed an additional aberrant band (Fig. [2c](#Fig2){ref-type="fig"}). This additional fragment corresponds to the recognition of the first guanine of the exon as the acceptor site (the mutation is a transition of G \> A), resulting in a frameshift effect starting at the first base of the exon. The *in silico* algorithms had predicted the same consequence (Table [4](#Tab4){ref-type="table"}).

Clinical description of RP1973 {#Sec16}
------------------------------

A remarkable case was RP1973, which was found to be a compound heterozygous for two nonsense mutations in *CEP250*. Both nonsense mutations segregate with the family, which is composed of both parents and an unaffected sibling (Fig. [3a](#Fig3){ref-type="fig"}). Patient RP1973 suffered from bilateral moderate-severe progressive hearing loss manifested at 13 years old (Fig. [3b](#Fig3){ref-type="fig"}) and late-onset progressive diminution of vision in both eyes with photophobia (first ophthalmologic examination at 44 years old). There is no history of any similar condition in any other family member. The BCVA was 0.6 in the right eye and 0.5 in the left eye (Snellen). The anterior segment findings were within normal limits, but fundus examination revealed migration of pigment in a bone-spicule pattern within a mid-peripheral annular zone of both eyes and narrowing of the peripheral retinal blood vessels (Fig. [3c](#Fig3){ref-type="fig"}). The left eye showed a glistening reflex of the inner retinal surface secondary to an epiretinal membrane. The macula of the right eye was relatively normal. Humphrey perimetry revealed peripheral visual field constriction with relative defects in the paracentral region in both eyes that has remained stable for the last five years. Macular autofluorescence images were normal in both eyes. The OCT shows a normal macular thickness with discontinuity of the outer segment layer of the photoreceptors around the foveal center in both eyes (Fig. [3c](#Fig3){ref-type="fig"}). Full-field electroretinography showed only mild alterations in the scotopic flash electroretinography (ERG), as the amplitudes of the b-wave were reduced in the right eye and absent in the left eye. Macular ERG showed an absence of response in both eyes, and Visual Evoked Potentials (VEP) were altered (Supplemental Fig. [S1](#MOESM1){ref-type="media"}). Due to the symptoms, the nature of the variants leading to a premature stop codon and the co-segregation analysis we consider both mutations as disease causing for an USH-like phenotype.Figure 3Clinical and molecular data of patient RP1973 harboring the nonsense mutations in *CEP250*. (**a**) Family pedigree with the Sanger sequencing results revealing the segregation pattern of the mutations. (**b**) Audiometric results evincing the progression of the bilateral hearing loss. (**c**) Ocular phenotype. Upper images correspond to the right eye, bottom images are from the left eye. Fundus pictures showing pigment clumps (c1, c4) and thinning of the peripheral arterioles (c2, c5). OCT images of the foveal region showing loss and discontinuity of the retinal pigment epithelium layer (c3, c6). Abbreviations: yo, years old; dB, decibel; Hz, hertz.

The analysis of the targeted panel and WES results showed no additional putative pathogenic mutations, except for one heterozygous missense variant in *USH2A* (rs773526991: c.4561C \> T/p.Arg1521Cys), presenting an allele frequency of 0.00002 in ExAC and for which the *in silico* tools implied a deleterious effect. Nevertheless, no other potential mutation was identified in *USH2A*.

Discussion {#Sec17}
==========

Usher syndrome is genetically heterogeneous mostly due to the high number of genes involved and their large size. The genetic etiopathogeny relies on all kinds of mutations among these genes and additionally, most of the variants are private. For that reason, it is very difficult to perform molecular diagnosis by conventional genotyping or direct gene sequencing. In our study, we were able to detect biallelic mutations in an USH gene in 45 out of the 58 previously unscreened patients (77.6%) and we identified 96 out of the 116 expected mutated alleles (82.8% detection ratio). That percentage difference is due to the fact that 6 cases were carriers of only one pathogenic variant (Table [3](#Tab3){ref-type="table"}). The remaining undiscovered second mutation, as well as both variants of unresolved cases, may be located either in other USH responsible still unknown genes or in other non-coding regions that were not incorporated in our design. The pathogenic deep intronic mutation c.7595 − 2144A \> G in *USH2A* was included in the study, but five other have been recently designated to be pathogenic^[@CR27]--[@CR29]^, which proves that still many deep intronic mutations may remain unveiled and further whole gene screen studies are of great interest.

The output of the analysis of the raw data is very dependent on the algorithm used for the mapping and variant calling. Two control variants, consisting of frameshift duplications, were detected only when relaxing the software quality parameters, suggesting a possible hindrance for the Ion Torrent mapping algorithm to align homopolymers. Indeed, other studies have reported these homopolymer-associated errors and even over and under-calling errors in non-homopolymer regions^[@CR32],[@CR33]^. Additional factors for this technology suggested by other authors, such as the biases produced by the GC content or the underestimation of the quality scores^[@CR32],[@CR34]^, probably contribute to the false negative calling errors.

The platform and panel design provided a 91% reliability based on the point mutation detection rate of the test group, but it reached a 100% of accuracy when thresholds of the mapping and annotation variables were decreased. However, no additional causative variants were found in the group of unresolved cases after applying the same procedure. Nevertheless, the failure to detect these variants could also fall on the HTS system used for the study, escaping variant detection independently on the resulting data management.

Among the study, two patients from the previously unscreened group presented mutations in genes that were not consistent with their clinical diagnosis, being these genes usually responsible for another USH subtype. One USH I patient (RP1748) carried biallelic mutations in *USH2A* and an USH II case in the *MYO7A* gene (RP1567). Still, the event of a molecular diagnosis not quite matching the clinical phenotype is not unusual and has been previously reported in other studies^[@CR8],[@CR35]^. Indeed, this supports the further investigation of USH patients by HTS to establish better genotype -- phenotype associations.

Many previous studies have evidenced the presence of large rearrangements among different USH populations, establishing them as a significant genetic alteration causing the disease. *PCDH15* and *USH2A* are the most common genes displaying such CNVs^[@CR30],[@CR36]^, but also large rearrangements have been found in *MYO7A*, *CDH23* and *ADGRV1*^[@CR37],[@CR38]^.

A CNVs survey based on the coverage of the sequencing results was not possible due to the wide deviation of the target enrichment technique by *loci* amplification. However, large homozygous deletions could be inferred from null covered regions corresponding to several adjacent probes, when observed in punctual cases. The supplemental analysis by MLPA or aCGH allowed us to detect a total of five large rearrangements among the test group and the previously unscreened cohort, four of these rearrangements being novel. Concerning our series of patients without prior genetic diagnosis, the CNVs account for 5.2% of the total identified pathogenic alleles.

Four of the novel mutations were intronic variants located in splicing regions that, though all but one were set on canonical ±1 *loci*, a sort of functional analysis would provide further support of their pathogenicity. Certainly, the minigene assays proved that all these four mutations cause an aberrant splicing.

Regarding the compound heterozygous case for the two nonsense mutations in *CEP250*, our study provides sufficient data for the gene to be classified as USH-like causative. The association was firstly introduced in a study of a consanguineous family of Iranian Jewish origin characterized by early onset hearing loss and mild RP^[@CR7]^ and, very recently, Kubota *et al*.^[@CR39]^ presented a Japanese family carrying compound heterozygous nonsense mutations in *CEP250*, with a clinical phenotype of cone-rod dystrophy and sensorineural hearing loss. Our patient with the *CEP250* mutations (RP1973) presented with progressive hearing loss and mild macular affectation with lowering of the visual acuity and photophobia, which are similar symptoms to those of the latter work, thus consolidating its role as a gene responsible for mimicking Usher syndrome. It has to be remarked that RP1973 shows a clearly progressive SNHL, yet the aforementioned studies do not give any details about the deafness evolution and, thus, a full comparative analysis is not feasible. There is another study correlating *CEP250* with non-syndromic RP (nsRP) due to a detected homozygous missense mutation^[@CR40]^. These findings are in agreement with ours and other authors observations that different diseases can be caused by the same gene depending on specific mutations, such as *USH2A* that can cause either nsRP or USH, or the USH genes *MYO7A*, *USH1C*, *CDH23*, *PCDH15*, *USH1G*, *WHRN* or *CIB2* that can cause non syndromic hearing loss or USH^[@CR41]--[@CR48]^. In view of the different but closely related phenotypes associated to *CEP250*, thorough clinical examinations of the cases should be performed to better understand the consequences of mutations in this gene, particularly those regarding cone affectation.

In the last years, the USH molecular diagnosis through HTS approaches have replaced the traditional techniques based on Sanger sequencing^[@CR35],[@CR49]^. The more recent next generation sequencing approaches enable a detection ratio between 50--100%, depending on the cohort and design of study^[@CR8],[@CR9],[@CR12],[@CR50]--[@CR53]^. Here, we provide a HTS method based on targeted exome library generation by amplification and the subsequent ion sensing-based sequencing that allows an average allele detection ratio compared to the other mentioned studies. It is, though, unfair to compare these varying efficiencies, since they do not only rely on the sequencing system, but also on the cohort selection criteria of the samples. For instance, the group analyzed by Qu *et al*.^[@CR53]^, Besnard *et al*.^[@CR50]^ and Eandi *et al*.^[@CR9]^ consisted of only five, thirteen and seventeen probands respectively, a rather scarce number of samples that might bias the efficiency outcome. Additionally, those and other studies such as Aparisi *et al*.^[@CR8]^ and Bonnet *et al*.^[@CR51]^ involved only well USH characterized patients. Our study not only included a larger number of samples, but also some unclassified USH cases. Therefore, another partial reason for the unsolved cases could be the misdiagnosis of some patients as USH, who could harbor several mutations in other genes that together may mimic the syndrome. From the seven unresolved patients without genetic diagnosis, three lack in detailed clinical notes that clearly support the cases as USH. The remaining four patients do not fully harmonize with the syndrome, since they present a late-onset hearing impairment. If we were not to take these samples into account, the detection ratio would increase from the 82.8% up to 94.1%. Even displaying such a solid outcome, this HTS approach falls short of CNV detection, yet it allows the use of only 10 ng of starting DNA (admitting as well some degradation). All these features shall be taken in consideration, depending on the requirements and resources of each center and the group of study.

Our updated custom design for USH targeted exome sequencing is a reliable tool for molecular diagnosis of the disease, and its implementation in the health care system would lead to a great profit for the patients. Furthermore, *CEP250* should be officially recognized as a gene causative of Usher-like syndrome.
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